CPA
ATOS icon

Capital Performance Advisors’s Atossa Therapeutics ATOS Stock Holding History

Capital Performance Advisors’s Portfolio ATOS Stock Details ATOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2
Closed -$38 – 388
2024
Q3 		$38 Buy
+2
New +$40 ﹤0.01% 2816

Other funds holding ATOS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital Performance Advisors's ATOS Position: Q4 2024 in Review

Capital Performance Advisors sold out of Atossa Therapeutics (ATOS) in Q4 2024, closing a stake of 2 shares — an estimated $38 sold.

Capital Performance Advisors first reported a position in ATOS in Q3 2024 and held it in 1 quarter. The position peaked at $38 in Q3 2024. 86 funds tracked by Wall St. Rank hold ATOS as of Q4 2024.

  • Capital Performance Advisors reported no remaining Atossa Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 2 Atossa Therapeutics shares in Q4 2024, an estimated $38.
  • Capital Performance Advisors first reported a position in Atossa Therapeutics in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Atossa Therapeutics position peaked at $38 in Q3 2024.
  • 86 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.